Skip to playerSkip to main content
  • 13 years ago
Kirkland's' Daniel Wolf tells The Deal Pipeline about his unique experience in advising Bristol-Myers Squibb in its $2.5 billion acquisition of Inhibitex.
Be the first to comment
Add your comment

Recommended